|
|
|
|
|
HIGHLIGHTS FROM THE 2024 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING |
|
|
|
|
|
|
| State-of-the-Art Lecture: Prostate Cancer Screening in High-Risk Groups
|
| Yaw Nyame, MD, MS, MBA
|
| Yaw Nyame's lecture at the 2024 AUA Annual Meeting highlighted the increased burden of prostate cancer among high-risk populations, particularly Black Americans and individuals with genetic predispositions like BRCA2 mutations. He emphasized the importance of initiating PSA testing between ages 40-45 and considering annual screening thereafter in these groups to maximize early detection while minimizing harm.
|
|
|
|
|
|
| AUA Guidelines: Salvage Therapy for Prostate Cancer
|
| Todd Morgan, MD
|
| Todd Morgan presented updated AUA guidelines for salvage therapy in prostate cancer. The guidelines emphasize early intervention with salvage radiation therapy when PSA levels are low and consideration of additional treatment factors such as PSA doubling time, Gleason Grade Group, and imaging results. They also recommend shared decision-making regarding the use and duration of ADT alongside radiation therapy, especially for patients with high-risk features like higher post-prostatectomy PSA, Gleason Grade Group 4 to 5, and seminal vesicle involvement.
|
|
|
|
|
|
|
Prostate Cancer: Advanced (Including Drug Therapy) I
|
|
| Differences in Barriers and Facilitators to First-Line Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer Between Urologists and Oncologists: A Sub-Analysis of the IMPLEMENT Study
|
| Stacy Loeb, MD
|
| Stacy Loeb presented a sub-analysis of the IMPLEMENT study comparing barriers and facilitators to first-line treatment intensification in metastatic castration-sensitive prostate cancer between urologists and oncologists. Common barriers identified included knowledge gaps about treatment outcomes and a tendency to delay intensification until second-line therapy. Facilitators included confidence in and comfort with managing treatment intensification.
|
|
|
|
|
|
| Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer |
| Geoffrey Gotto, MD, MPH, FRCSC |
| Geoffrey Gotto presented the third interim analysis of the DARolutamide ObservationaL (DAROL) study at the 2024 AUA meeting, focusing on patients with nmCRPC. The study assessed the real-world safety and effectiveness of darolutamide, a potent androgen receptor inhibitor. The results showed a favorable safety profile consistent with previous trials (ARAMIS), with low incidence of treatment-emergent adverse events. |
|
|
|
|
|
| Analyzing the Percentage of Positive 68Ga-PSMA-PET/CT Scans Based on PSA Ranges Across Distinct Indications for the Scan |
| Maya Ataya, MD |
| Prostate cancer is the leading incident cancer among men, and population growth and aging have fueled a 40% rise in global case burden since 2006. Despite recent improvements in treatment, patients with locally advanced and advanced prostate cancer experience significant emotional distress, diminished quality of life, and increased risk of cancer-specific mortality.
|
|
|
|
|
|
|
|
|
|
|
| Prostate-Specific Antigen Dynamics from the Phase 3 EMBARK Trial: A Post-Hoc Analysis |
| Stephen Freedland, MD |
| Stephen Freedland presented a post hoc analysis of the EMBARK trial at the 2024 AUA meeting, focusing on PSA dynamics in patients with high-risk biochemical recurrence of prostate cancer. The study evaluated patients treated with enzalutamide combination therapy, enzalutamide monotherapy, or leuprolide alone. Key findings included a higher proportion of patients achieving undetectable PSA levels with enzalutamide, earlier time to undetectable PSA, and successful re-achievement of undetectable PSA levels after treatment re-initiation. |
|
|
|
|
|
| Quality of Treatment with Targeted Therapies for Advanced Prostate Cancer by Specialist: Do Patients Who Are Managed by Urologists Fare Differently?
|
| Kassem Faraj, MD
|
| Kassem Faraj presented an analysis at the 2024 AUA meeting evaluating whether the quality of treatment with targeted therapies for advanced prostate cancer differed based on the treating specialist. The study used data from the National Medicare claims database (2011 – 2019) and focused on outcomes related to cardiometabolic adverse events, monthly out-of-pocket costs, and treatment adherence.
|
|
|
|
|
|
| Phase I Dose-Escalation Trial of Multiple and Fractionated-Dose PSMA-Targeted Alpha Radionuclide (225Ac-J591) for Metastatic Castration-Resistant Prostate Cancer |
| Michael Sun, MD |
| Michael Sun presented the results of a phase 1 dose-escalation trial of multiple and fractionated-dose PSMA-targeted alpha radionuclide (225Ac-J591) for mCRPC. This trial aimed to evaluate the feasibility and efficacy of fractionated dosing with 225Ac-J591, building on the success of similar approaches with other radionuclides like 177Lu-J591 and 177Lu-PSMA-617. |
|
|
|
|
|
